
 
Lily Yang, MD, PhD
Dr. Yang's CV (PDF)
| Primary Appointments |
 |
Nancy Panoz Chair of Surgery in Cancer Research, Emory University School of Medicine |
 |
Associate Professor, Surgical Oncology Research, Department of Surgery,
Emory University School of Medicine |
| Joint Appointment |
 |
Assistant Professor, Department of Hematology/Oncology, Winship Cancer Institute |
| Secondary Appointment |
 |
Faculty Member; Graduate Programs in Biochemistry, Cell and Developmental Biology (BCDB) and Molecular Systemic Pharmacology (MSP); Emory University School of Medicine |
| Telephone |
 |
404.778.4269 |
| Education |
 |
MD, Department of Medicine, West China University of Medical Sciences,
Chengdu, Sichuan Province, China, 1978-1983 |
 |
Master of Medicine, Microbiology
and Immunology, Institute of Epidemiology and Microbiology, Chinese Academy
of Preventive Medicine, Beijing, China, 1983-1986 |
 |
PhD, Program in Molecular
and Cell Biology & Biochemistry, Brown University, Providence, RI,
1988-1993 |
| Postgraduate Training |
 |
Research Associate, Department of Immunology, Beijing Institute for Cancer
Research, Beijing, China, 1986-1988 |
 |
Postdoctoral Associate, Brown University-Rhode
Island Hospital, 1993 |
 |
Research Associate and Director of Animal Study,
University of Southern California School of Medicine, Los Angeles, CA,
1993-1995 |
 |
Research Associate, Emory, 1995-1996 |
 |
Research Fellow, Group Leader
For Anti-Angiogenesis Pre-Clinical Study, Aventis Gencell, Hayward, CA,
1998-1999 |
| Honors and Awards |
 |
Avon Scholar Award for Breast Cancer Research, 2001-2002 |
| Current Editorial Boards |
 |
Apoptosis |
 |
Frontiers in Bioscience |
| Current Organizational Memberships |
 |
American Association for Cancer Research |
 |
American Academy of Nanomedicine, Fellow |
 |
Breast Cancer Research Program, Department of Defense, Synergistic Idea Awards (SIA-3) Panel |
 |
Pathogenesis Committee, California Breast Cancer Research Program |
 |
Society of Molecular Imaging |
| Current Research Interests |
The development of novel approaches for detection and treatment of human cancer, with specific projects including: |
|
|
 |
Investigation of the mechanisms of apoptosis resistance and the feasibility of targeting members of the inhibitor of apoptosis family proteins such as survivin and XIAP for induction of specific tumor cell death and for sensitization of cancer cells to chemotherapy. |
 |
Examination of the mechanisms of tumor hypoxia in resistance to therapy and tumor progression. |
 |
Development of molecular beacon technology to detect cancer cells based on fluorescence imaging of tumor marker gene expressing cells. |
 |
Development of multifunctional and tumor targeted nanoparticles for non-invasive tumor imaging and delivery of therapeutic drugs. |
| Year Joined Emory as a Faculty
Member |
 |
1997 |
return to top
|